A hi-tech prostate cancer drug that offers hope to men who have run out of treatment options became available in the UK today.
Enzalutamide is licensed for patients with advanced prostate cancer who are no longer responding to hormone treatments or chemotherapy.
What to expect from the new drug:
- The new pill will cost around £2,500 a month.
- It can extend the lives of patients no longer being treated by almost five months.
- Seven out of 10 of the men in the Phase III Affirm trial taking enzalutamide were still alive after one year.
- It has a relative lack of side effects.
- The drug known as Xtandi, blocks molecular signals that allow the male hormone testosterone to fuel prostate cancer.
- It targets three different steps of the signalling pathway.
More top news
Model Rosie Nelson writes for ITV News, revealing why she is calling for MPs to pass a new law protecting models from becoming too skinny.
Amid calls for new laws to regulate the size of models, we look at how the face of fashion has changed over the past 60 years.
Amid calls for new laws to prevent models getting too thin, ITV News speaks to three women in the fashion industry to get their views.